Literature DB >> 28454044

Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis.

M Eugenia Socías1, Evan Wood1, Ryan McNeil1, Thomas Kerr1, Huiru Dong2, Jean Shoveller3, Julio Montaner1, M-J Milloy4.   

Abstract

BACKGROUND: In February 2014, several regulatory reforms were introduced to the methadone maintenance treatment (MMT) program in British Columbia, Canada, including a switch to a ten-times more concentrated methadone formulation and restrictions in pharmacy delivery services. We evaluated possible unintended effects of these changes on illicit drug use patterns and HIV treatment outcomes among HIV-positive opioid users.
METHODS: Data was drawn from ACCESS, a prospective community-recruited cohort of HIV-positive people who use illicit drugs in Vancouver, Canada. Interrupted Time Series Analyses were used to evaluate impacts of the policy change on monthly rates of MMT enrolment, illicit heroin injection, antiretroviral therapy (ART) adherence, and HIV viral suppression among HIV-positive opioid users between November 2012 and May 2015.
RESULTS: A total of 331 HIV-positive opioid users were included. The MMT policy change led to a significant immediate 11.5% increase in heroin injection, and 15.9% drop in optimal ART adherence. A gradual increase in the prevalence of MMT enrolment after the policy change was also documented (0.9% per month). No changes in viral suppression rates were observed.
CONCLUSION: We observed immediate increases in illicit heroin injection and decreases in ART adherence in the wake of regulatory changes to the local MMT program. These findings underscore the need to consider potential unintended effects of altering health programmes for vulnerable populations, the need to develop appropriate mitigation strategies, as well as to involve all relevant stakeholders in the planning and implementations of new policies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; HIV; Health policies; Methadone maintenance treatment; Opioid agonist treatment; Opioid use disorders

Mesh:

Substances:

Year:  2017        PMID: 28454044      PMCID: PMC5820001          DOI: 10.1016/j.drugpo.2017.03.008

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  29 in total

1.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

Review 2.  Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review.

Authors:  Nicholas B King; Veronique Fraser; Constantina Boikos; Robin Richardson; Sam Harper
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

3.  Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART).

Authors:  Shilpa Viswanathan; Roger Detels; Shruti H Mehta; Bernard J C Macatangay; Gregory D Kirk; Lisa P Jacobson
Journal:  AIDS Behav       Date:  2015-04

4.  HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Authors:  Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

5.  The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities.

Authors:  M W Langendam; H J van Haastrecht; E J van Ameijden
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

Review 6.  Beyond virological suppression: the role of adherence in the late HAART era.

Authors:  Adriana Ammassari; Maria Paola Trotta; Noga Shalev; Patrizia Marconi; Andrea Antinori
Journal:  Antivir Ther       Date:  2012-03-13

7.  The consequences of a change in formulation of methadone prescribed in a drug clinic.

Authors:  M D Steels; M Hamilton; P C McLean
Journal:  Br J Addict       Date:  1992-11

Review 8.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.

Authors:  Georgie J MacArthur; Silvia Minozzi; Natasha Martin; Peter Vickerman; Sherry Deren; Julie Bruneau; Louisa Degenhardt; Matthew Hickman
Journal:  BMJ       Date:  2012-10-03

9.  Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey.

Authors:  Alissa M Greer; Sherry Hu; Ashraf Amlani; Sarah Moreheart; Olivia Sampson; Jane A Buxton
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-01-14

Review 10.  Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Andrea J Low; Gitau Mburu; Nicky J Welton; Margaret T May; Charlotte F Davies; Clare French; Katy M Turner; Katharine J Looker; Hannah Christensen; Susie McLean; Tim Rhodes; Lucy Platt; Matthew Hickman; Andy Guise; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2016-06-25       Impact factor: 9.079

View more
  9 in total

1.  Trajectories of retention in opioid agonist therapy in a Canadian setting.

Authors:  M Eugenia Socías; Huiru Dong; Evan Wood; Rupinder Brar; Lindsey Richardson; Kanna Hayashi; Thomas Kerr; M-J Milloy
Journal:  Int J Drug Policy       Date:  2020-02-09

2.  Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review.

Authors:  Katrina Bouzanis; Siddharth Joshi; Cynthia Lokker; Sureka Pavalagantharajah; Yun Qiu; Hargun Sidhu; Lawrence Mbuagbaw; Majdi Qutob; Alia Henedi; Mitchell A H Levine; Robin Lennox; Jean-Eric Tarride; Dale Kalina; Elizabeth Alvarez
Journal:  BMJ Open       Date:  2021-09-23       Impact factor: 3.006

3. 

Authors:  Matias Raski; Christy Sutherland; Rupinder Brar
Journal:  Can Fam Physician       Date:  2020-11       Impact factor: 3.275

4.  From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia.

Authors:  Matias Raski; Christy Sutherland; Rupinder Brar
Journal:  Can Fam Physician       Date:  2020-11       Impact factor: 3.275

5.  Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.

Authors:  M Eugenia Socias; Evan Wood; Huiru Dong; Rupinder Brar; Paxton Bach; Sean M Murphy; Nadia Fairbairn
Journal:  Contemp Clin Trials       Date:  2020-03-16       Impact factor: 2.226

6.  Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.

Authors:  M Eugenia Socías; Evan Wood; Thomas Kerr; Seonaid Nolan; Kanna Hayashi; Ekaterina Nosova; Julio Montaner; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2018-05-29       Impact factor: 4.492

7.  Prevalence and longitudinal correlates of recent exposure to fentanyl among HIV-positive people who use unregulated drugs during a community-wide overdose crisis.

Authors:  Soroush Moallef; Ekaterina Nosova; Seonaid Nolan; Nadia Fairbairn; Jane Loh; Kanna Hayashi; M-J Milloy
Journal:  AIDS Care       Date:  2021-03-25

8.  The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.

Authors:  Lindsay Mackay; Thomas Kerr; Nadia Fairbairn; Cameron Grant; M-J Milloy; Kanna Hayashi
Journal:  Addict Sci Clin Pract       Date:  2021-04-28

9.  Day-to-day impact of COVID-19 and other factors associated with risk of nonfatal overdose among people who use unregulated drugs in five cities in the United States and Canada.

Authors:  Soroush Moallef; Becky L Genberg; Kanna Hayashi; Shruti H Mehta; Gregory D Kirk; JinCheol Choi; Kora DeBeck; Michele Kipke; Richard D Moore; Marianna K Baum; Steven Shoptaw; Pamina M Gorbach; Brian Mustanski; Marjan Javanbakht; Susanne Siminski; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2022-09-15       Impact factor: 4.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.